Technology
The product claim has to be earned by the signal.
DryNight is evaluating whether a wearable lower-abdomen sensor can detect bladder filling early enough to trigger a private cue. Ultrasound is the lead candidate, but the architecture remains open until feasibility work proves the best path.
Product thesis
Measure bladder state, not wet fabric.
The starting technical hypothesis is that a lower-abdomen wearable can estimate bladder filling well enough to trigger a private pre-void cue. Ultrasound is the lead candidate because external academic work has explored abdomen-worn bladder monitoring, but DryNight will evaluate the best sensing path before locking hardware.
Design constraints
- 01 Pediatric nocturnal enuresis as the first product focus
- 02 Miniaturized ultrasound as the lead sensing candidate
- 03 Bioimpedance and other noninvasive signals evaluated in parallel
- 04 Cordless adhesive patch and private haptic wristband cue
- 05 Data minimization from the first prototype
- 06 Exploratory hardware conversations before partner claims are made
Schematic
Current household tools
- Cord-and-clip moisture alarms
- Signal after wetness begins
- Public sound in a private moment
- Repeated cleanup after the event
DryNight thesis
- Cordless lower-abdomen sensing
- Signal before wetness begins
- Private cue to child or caregiver
- Design centered on dignity and sleep
System architecture
A signal path designed for trust.
The intended architecture keeps raw signal data close to the device, sends only minimal threshold information to paired devices, and separates research telemetry from day-to-day family use.
01
Patch
Lower-abdomen sensor candidate designed for overnight wear.
02
Signal model
Algorithms tested only after bench data proves a usable bladder-filling signal.
03
Pairing
Minimal threshold information sent to a wristband and caregiver device.
04
Alert
Private haptic cue for the child, with caregiver notification as a family choice.
Evidence status
The site should make clear what is known, and what still has to be proven.
DryNight is not presenting product performance data yet. The evidence plan starts with external precedent, hardware feasibility, usability, and then clinical validation. That sequence matters because investor confidence depends on the discipline of the claim.
External precedent
Academic groups have explored abdomen-worn bladder monitoring and pre-void alerting. DryNight will cite specific publications only after each claim is verified against the primary source.
Evidence review in progress
Sensor decision
Miniaturized ultrasound is the lead candidate, but the device architecture should stay open until bench testing compares signal quality, comfort, power, cost, and manufacturability.
Hardware path under review
Regulatory posture
No diagnostic, treatment, clearance, or approval claim belongs on the site until regulatory counsel and clinical advisors have reviewed the intended use.
Not cleared or approved
Clinical partners
The first partner conversations should focus on study design, family burden, usability, and the minimum evidence required before making commercial claims.
Partner with us
Contact
DryNight is early. The right conversations matter now.
The useful next step is not a waitlist count. It is a focused group of parents, clinicians, engineers, operators, and investors who can pressure-test the product before the claims get ahead of the evidence.
Investor inquiries should focus on feasibility, evidence plan, and the path to a defensible first prototype.